Background/Aims: Skeletal muscle atrophy is an important health issue and can impose tremendous economic burdens on healthcare systems. Glucocorticoids (GCs) are well-known factors that result in muscle atrophy observed in numerous pathological conditions. Therefore, the development of effective and safe therapeutic strategies for GC-induced muscle atrophy has significant clinical implications. Some natural compounds have been shown to effectively prevent muscle atrophy under several wasting conditions. Dihydromyricetin (DM), the most abundant flavonoid in Ampelopsis grossedentata, has a broad range of health benefits, but its effects on muscle atrophy are unclear. The purpose of this study was to evaluate the effects and underlying mechanisms of DM on muscle atrophy induced by the synthetic GC dexamethasone (Dex). Methods: The effects of DM on Dex-induced muscle atrophy were assessed in Sprague-Dawley rats and L6 myotubes. Muscle mass and myofiber cross-sectional areas were analyzed in gastrocnemius muscles. Muscle function was evaluated by a grip strength test. Myosin heavy chain (MHC) content and myotube diameter were measured in myotubes. Mitochondrial morphology was observed by transmission electron microscopy and confocal laser scanning microscopy. Mitochondrial DNA (mtDNA) was quantified by real-time PCR. Mitochondrial respiratory chain complex activities were examined using the MitoProfile Rapid Microplate Assay Kit, and mitochondrial membrane potential was assessed by JC-1 staining. Protein levels of mitochondrial biogenesis and dynamics markers were detected by western blotting. Myotubes were transfected with siRNAs targeting peroxisome proliferatoractivated receptor γ coactivator 1α (PGC-1α), mitochondrial transcription factor A (TFAM) and mitofusin-2 (mfn2) to determine the underlying mechanisms. Results: In vivo, DM preserved muscles from weight and average fiber cross-sectional area losses and improved grip strength. In vitro, DM prevented the decrease in MHC content and myotube diameter. Moreover, DM stimulated mitochondrial biogenesis and promoted mitochondrial fusion, rescued the 
Introduction
Skeletal muscle accounts for almost 40% of the total body mass, and the maintenance of healthy skeletal muscles is vital for providing energy for locomotion, preventing metabolic disorders and promoting healthy aging [1] [2] [3] . Many pathological conditions characterized by muscle atrophy, including cachexia, diabetes, sepsis, starvation, metabolic acidosis and chronic kidney disease, are associated with elevated circulating glucocorticoid (GC) levels [4] . Meanwhile, high doses or sustained administration of the exogenous synthetic GC dexamethasone (Dex) in clinical treatment causes muscle atrophy, which increases morbidity and mortality [5] . Thus, the identification of new targets and development of effective and safe therapeutic avenues are urgent medical needs to prevent GC-induced muscle atrophy.
The pivotal role of mitochondrial dysfunction in promoting muscle atrophy has been revealed in the past several years [6] [7] [8] [9] [10] [11] . Recently, several studies demonstrated that mitochondrial dysfunction precedes and activates muscle atrophy signaling in Dex-induced muscle atrophy models [12] and some natural plant extracts, including hydroxytyrosol acetate, resveratrol and quercetin, can target the mitochondria to improve mitochondrial function and prevent muscle atrophy under several wasting conditions [12] [13] [14] . Thus, development of drugs or nutrients that improve mitochondrial function could be beneficial in preventing Dex-induced muscle atrophy. Ampelopsis grossedentata, a medicinal and edible plant growing in mountainous areas of southern China, has been consumed as a health tea and traditional medicine for hundreds of years [15] . Dihydromyricetin (DM) is the main flavonoid component of A. grossedentata, and the DM contents can be greater than 30% in vine tea made from its tender stems and leaves [16] . DM displays a broad range of biological and pharmacological activities such as antioxidant, anti-inflammatory, anti-tumor, neuroprotective and hepatoprotective effects [17] [18] [19] [20] [21] . Our previous studies demonstrated that DM could improve skeletal muscle insulin resistance and stimulate myokine secretion [22] [23] [24] . Importantly, we verified that DM could reverse mitochondrial dysfunction in skeletal muscle under acute hypoxic conditions, which contributes to improvements in physical performance [25] . However, no information is available regarding the effects of DM on skeletal muscle atrophy. The purpose of this study was to determine whether DM could improve mitochondrial function and attenuate Dex-induced muscle atrophy. The underlying mechanisms were also examined.
Mitochondrial biogenesis and dynamics are crucial for maintaining normal mitochondrial function [26] . Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a critical regulator of mitochondrial biogenesis, can control the expression of mitochondrial DNA (mtDNA)-encoded intramitochondrial proteins by regulating mitochondrial transcription factor A (TFAM) levels [27] . In addition, PGC-1α has been shown to modulate mitochondrial dynamics by stimulating mitofusin (mfn1 and mfn2) gene expression [28] . Importantly, the maintenance of high PGC-1α levels in muscles preserves mitochondrial function and prevents muscle atrophy during disuse atrophy, sarcopenia, fasting and cachexia [29] [30] [31] [32] . Previous studies have demonstrated that Dex suppressed PGC-1α expression levels both in vivo and in vitro [33] [34] ; thus, treatments that preserve and increase PGC-1α levels and signaling may be a plausible strategy to counteract Dex-induced muscle atrophy. We previously showed that DM treatment significantly increased the levels of PGC-1α in skeletal muscle both in vivo and in vitro [24] . These findings led us to hypothesize that DM could attenuate Dex-induced muscle atrophy by reversing mitochondrial dysfunction through the PGC-1α signaling pathway. As expected, our results confirmed, for the first time, that DM attenuated Dex-induced muscle atrophy by improving mitochondrial function, which was mediated in
Animal studies
Adult male Sprague Dawley (SD) rats (n = 50) with an average body weight of 200 ± 24 g were purchased from the Experimental Animal Center of the Third Military Medical University (Chongqing, China). Rats were housed in a specific pathogen free (SPF) grade room at a controlled temperature (22 ± 2 °C) with a 12 h light/dark cycle and had ad libitum access to food and water. All animal care and experimental procedures were conducted according to institutional guidelines with the approval of the Institutional Animal Care and Use Committee of the Third Military Medical University.
After acclimatization for 1 week, rats were randomized into five groups (n=10 per group): control group (Control); Dex-treated group (Dex); Dex plus 50 mg/kg body weight DM (DM50); Dex plus 100 mg/ kg body weight DM (DM100); Dex plus 200 mg/kg body weight DM (DM200). DM was dissolved in distilled water, and the Control group was given the same dose of distilled water as the placebo. DM was administered by gavage every day for 14 days prior to Dex treatment and maintained throughout the experimental period. Dex (500 μg/kg body mass) was administered intraperitoneally once a day for 10 days. The Control group received an equal volume of normal saline. Body weight and food intake were assessed daily. Grip strength was measured with a grip strength meter (YuYan Instruments, Shanghai, China).
After the 24 day treatment, rats were sacrificed under anesthesia. Blood was collected and centrifuged at 3, 500 rpm for 6 min. The serum creatine kinase (CK) level was measured in an automatic analyzer (OLYMPUS AU5400, Japan). Gastrocnemius (GAS) and tibialis anterior (TA) muscles were quickly removed and collected for analyses.
Measurement of cross-sectional area (CSA)
Skeletal muscle tissues were dissected, fixed in fresh 4% paraformaldehyde solution and embedded in paraffin. For histological analysis, the paraffin sections were cut into slices (5 μm) for hematoxylin and eosin (H&E) staining. The images were captured with an Olympus VS120 microscope. The myofiber CSAs were determined for at least 500 fibers per GAS muscle, and the mean CSA was calculated. ImageJ software (NIH) was used for these analyses, which were conducted in a blinded fashion with the investigator being unaware of the group from which the images originated.
Observation of mitochondrial morphology using transmission electron microscopy (TEM)
Mitochondrial morphology in the GAS muscles was analyzed by TEM. GAS muscles from each group were trimmed into approximately 1.0 mm Cell transfection siRNAs for PGC-1α (sc-72151), TFAM (sc-156067) and mfn2 (sc-156013) were purchased from Santa Cruz Biotechnology along with control siRNA (sc-44230) and siRNA Transfection Reagent (sc-29528). The siRNA for FoxO3a was synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). L6 myotubes were transfected with 100 nM siRNA for 6 h according to the manufacturer's protocol. Then, the myotubes were switched into fresh medium for an additional 24 h. Where indicated, myotubes were treated with Dex and DM for 24 h. Thereafter, myotubes were used for subsequent experiments.
Measurement of myotube diameter
For determination of myotube diameter, myotube cultures were photographed under a phase contrast microscope at 100× magnification. The myotube diameters were measured in a total of 60 myotubes from at least 10 random fields from each photograph using ImageJ software (NIH) as previously described [37] . The results were expressed as a percent of the control.
Quantification of mtDNA mtDNA was extracted from GAS muscles and L6 myotubes using the Mito DNA Extraction Kit (Genmed Scientifics Inc., USA) according to the manufacturer's instructions. For the determination of the relative mtDNA copy number, the levels of mitochondrial ND1 (NADH-CoQ oxidoreductase 1) relative to the standard ACTB were evaluated by quantitative PCR using a qTower 2.2 real-time PCR system (Analytik Jena, German). The primer sequences are listed below: ND1 (forward: 5'-TTAATTGCCATGGCCTTCCTCACC-3'; reverse: 5'-TGGTTAGAGGGCGTATGGGTTCTT-3'); ACTB (forward: 5'-CCACCATGTACCCAGGCATT-3'; reverse: 5'-CGGACTCATCGTACTCCTGC-3'). Relative transcript abundance was calculated using the delta delta cycle threshold (ΔΔCt) method.
Measurement of oxidative phosphorylation complex activities and ATP levels
Mitochondria were isolated from GAS muscles or myotubes using Mitochondria Isolation Kits (Beyotime, China) according to the manufacturer's protocol. The activities of complexes I, II, and IV and ATP synthase were assessed in mitochondrial homogenates of GAS muscles or myotubes using the MitoProfile Rapid Microplate Assay Kit (catalog nos. ab 109721, ab 109908, ab 109911, and ab 109714, respectively; Abcam, Cambridge, MA, USA) according to the manufacturer's instructions. ATP levels were measured in the whole muscle lysates using the ATP Assay Kit (Beyotime, China) following the manufacturer's instructions. The total and mitochondrial protein concentrations were determined using the BCA Protein Assay Kit (Beyotime, China).
Measurement of MDA content and protein carbonyl levels MDA content was measured as an indicator of lipid oxidative damage in GAS muscles or myotubes using the MDA Detection Kit (Beyotime, China) according to the manufacturer's instructions. Protein carbonyl levels were determined as an indicator of protein oxidative damage in GAS muscles or myotubes 
Measurement of mitochondrial oxygen consumption rate (OCR)
L6 cells were seeded in XF Cell Culture Microplates. After differentiation and treatment, the cells were changed to unbuffered XF Base Medium supplemented with 1 mM pyruvate, 2 mM glutamine and 10 mM glucose and incubated at 37 °C in a non-CO2 incubator for 1 h. Then, the OCR was measured by the Extracellular Flux Analyzer (Seahorse Bioscience, Massachusetts, USA) as previously described [38] . The data were analyzed using Wave and Report Generator software.
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential (Δψm) was assessed in GAS muscles or myotubes using the JC-1 probe (Beyotime, China). Red fluorescence represents JC-1 J-aggregates, whereas green fluorescence represents the monomeric form of JC-1. For muscle tissues, isolated mitochondria were immediately suspended in a JC-1 staining solution and analyzed by an Infinite™ M200 Microplate Reader following the manufacturer's instructions. The Δψm in each group was calculated as the ratio of red/green fluorescence.
For myotubes, cells were cultured in a cell culture dish. After the indicated treatment, cells were incubated with a JC-1 staining solution for 20 min at 37 °C. Images were obtained using a Zeiss confocal laser scanning microscopy (Carl Zeiss, LSM 800). The red and green fluorescence intensities were quantified using the Zeiss LSM Image Examiner software. The Δψm was reflected by the ratio of red to green fluorescence intensity. The results were obtained from at least 30 cells in each of three experiments per group.
Visualization of mitochondrial network in L6 myotubes
Cells were grown on coverslips inside a cell culture dish. After treatment, the culture medium in the dish was replaced with prewarmed staining solution containing 250 nM MitoTracker Deep Red probe. Cells were incubated with the staining solution for 30 min at 37 °C. After staining was complete, the cells were washed two times with prewarmed PBS and incubated with fresh prewarmed media. Then, the cells were visualized using a Zeiss confocal laser scanning microscope. Mitochondrial mass was analyzed by quantifying the mitochondrial fluorescence intensity using Zeiss LSM Image Examiner software. The results were obtained from at least 30 cells in each of three experiments per group.
Measurement of reactive oxygen species (ROS) levels and mitochondrial-derived O 2
•− levels in L6 myotubes Total levels of cellular ROS in L6 myotubes were determined using the ROS Assay Kit (Beyotime, China) according to the manufacturer's instructions. For the analysis of mitochondrial O 2
•−
, L6 myotubes were labeled with MitoSOX Red, a highly selective fluorescent probe, for the detection of O 2
•− generated within mitochondria. Briefly, cells were cultured in a cell culture dish and were treated as indicated. MitoSOX Red reagent stock solution was diluted in HBSS/Ca/Mg buffer to generate a 5 μM reagent working solution. Cells were then incubated with 5 μM MitoSOX Red reagent working solution in the dark at 37 °C for 10 min. After three washes with warm buffer, live imaging was performed using a Zeiss confocal laser scanning microscope. The fluorescence intensity was quantified using the Zeiss LSM Image Examiner software. The results were obtained from at least 30 cells in each of three experiments per group.
Western blot analysis GAS muscle tissues were homogenized on ice in a Tissue Protein Extraction Reagent supplemented with a protease inhibitor (Roche Applied Science, Germany). Myotubes were homogenized on ice in RIPA lysis buffer (Beyotime, China) supplemented with PMSF. For the analysis of mitochondrial proteins, the isolated mitochondria from GAS muscles or myotubes were homogenized in the mitochondrial lysis buffer supplemented with PMSF (Beyotime, China). The lysates were centrifuged at 12, 000 g for 20 min at 4 °C and the supernatants were collected. Then, the protein samples were subjected to 10-15% SDS-PAGE, transferred to PVDF membranes (Bio-Rad), blocked with 5% skim milk for 2 h, incubated overnight at 4 °C with primary antibodies and then incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h. Protein bands were visualized using an enhanced chemiluminescence system (Millipore, Billerica, MA, USA) and densitometric analysis was performed using Quantity One software (Bio-Rad Lab., Hercules, CA, USA).
Statistical analysis SPSS 13.0 statistical software (SPSS Inc., Chicago, IL) was used for statistical analyses. Quantitative data are expressed as the mean ± standard deviations (SD). Statistical comparisons were conducted using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test for multiple comparisons. P < 0.05 was considered statistically significant. 
Results

DM attenuated Dex-induced muscle atrophy and dysfunction in SD rats
The baseline body weight was similar in each group. After treatment, Dex caused a significant decrease in the body weight compared to the control group, while the DM-200 group had a higher final body weight than the Dex-group (Fig. 1a) . In addition, there was no significant difference in the average food intake between the Dex-group and DM-treated groups. Consistent with the decrease in body weight, Dex caused a marked decline in the weights of both the GAS and TA muscles as well as the muscle/body weight ratio compared to the control group ( Fig. 1b and 1c) . The DM-100 and DM-200 groups had higher GAS muscle weights and GAS muscle/body weight ratios than the Dex-group, and the DM-200 group had higher TA muscle weights and TA muscle/body weight ratio than the Dex-group (Fig. 1b and 1c) . Histologically, Dex induced a significant decrease in the average myofiber CSA in GAS muscles, while the DM-100 and DM-200 groups exhibited an increase in the average fiber CSA of the GAS muscles compared to the Dex-group ( Fig. 1d and 1e ). These results suggested that DM treatment preserved GAS muscles from weight and average fiber CSA loss. Paralleling the changes in muscle mass, muscle function, assessed by grip strength, was improved in the DM-200 group compared to the Dex-group (Fig. 1f) . Additionally, the serum levels of CK, a well-known biomarker of muscle damage, were increased by Dex but were reduced in the DM-100 and DM-200 groups compared to the Dex-group (Fig. 1g ). Taken together, these results suggested that DM treatment attenuated Dex-induced muscle atrophy and dysfunction in SD rats.
DM attenuated Dex-induced mitochondrial injuries and modulated related protein expression
The mitochondrial morphology changes in the intermyofibrillar mitochondria (IFM) were observed by TEM. The Dex-group showed swollen and atypical mitochondrial with irregular and fragmented cristae, while DM treatment efficiently counteracted the mitochondrial morphological abnormalities, with less swollen mitochondrial and more intact cristae compared to the Dex-group (Fig. 2a) . The quantitative analysis of mitochondria revealed that the number of IFM in the Dex-group decreased compared to the control group, while the number of IFM in the DM-100 and DM-200 groups increased compared to the Dexgroup (Fig. 2b) . Similar results were observed for the percentage of normal mitochondria (Fig. 2c) .
To further elucidate the alterations in mitochondrial morphology and number, we evaluated mitochondria-related protein expression. Levels of PGC-1α and TFAM, key molecules related to mitochondrial biogenesis, were decreased by Dex but were increased in the DM-200 group compared to the Dex-group (Fig. 2d and 2e) . Similar results were observed for mfn2 expression ( Fig. 2d and 2e) . However, mfn1 and the mitochondrial fission protein drp1 were not affected by Dex or DM ( Fig. 2d and 2e) . Additionally, OPA1 expression was downregulated in the Dex-group compared to that in the control group, while no obvious changes in the levels of the OPA1 protein were observed after DM treatment ( Fig.  2d and 2e) . We also quantified the mitochondria-related protein levels in the mitochondrial subfractions. Consistent with the changes in TFAM, OPA1, mfn1 and mfn2 protein contents in the whole muscle lysates, the levels of TFAM and mfn2 in the mitochondrial subfractions were increased in the DM-200 group compared to the Dex-group, and the OPA1 and mfn1 levels remained unchanged upon treatment with DM ( Fig. 2f and 2g) . Inconsistent with the changes in drp1 levels in the whole muscle lysates, the levels of drp1 in the mitochondrial subfractions were increased by Dex but were reduced in the DM-100 and DM-200 groups compared to the Dex-group (Fig. 2f and 2g) . Moreover, the expression of Tom20, an accepted mitochondrial marker protein, was decreased upon Dex treatment but was increased in the DM-200 group compared to the Dex-group (Fig. 2h and 2i) . Furthermore, treatment with DM at 100 and 200 mg/kg body weight significantly inhibited Dex-induced loss of mtDNA content as evidenced by the restoration of the mtDNA/nDNA ratio (Fig. 2j) .
DM suppressed the collapse of mitochondrial membrane potential, protected against reduced activities of mitochondrial respiratory chain complexes, and alleviated oxidative stress in skeletal muscle tissues
We then investigated the effects of DM on mitochondrial function in GAS muscles. The results showed that Dex induced the loss of mitochondrial membrane potential (Δψm) Cellular Physiology and Biochemistry
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indicated by a decrease in the red/green fluorescent ratio, while DM treatment at 200 mg/ kg body weight repressed the changes of Δψm induced by Dex (Fig. 3a) . Moreover, the Dexgroup had lower complex I, II, and IV and ATP synthase activities than the control group, while the DM-200 group had higher activities of all the above complexes ( Fig. 3b-e) . Similar results were observed for ATP levels (Fig. 3f) . Mounting evidence suggests that mitochondria are the primary source of ROS [39] , and reduced activities of the mitochondrial respiratory chain complexes can result in the overproduction of mitochondrial ROS (mtROS) at the expense of ATP production [40] . Moreover, excessive mtROS production can promote oxidative stress and cause oxidative damage in tissues [41] . To explore the effects of Dex and DM on oxidative stress in GAS muscles, we examined the protein carbonyl levels as markers for protein oxidative damage and MDA content for lipid oxidative damage. The data showed that DM treatment at 100 and 200 mg/kg body weight markedly prevented Dex-induced elevation of protein carbonyl levels and MDA content ( Fig. 3g and 3h) . Together, these results suggested that DM treatment efficiently attenuated Dex-induced muscle mitochondrial dysfunction in vivo.
DM attenuated Dex-induced muscle atrophy in vitro
To confirm the findings obtained in SD rats, we further examined the effects of DM on Dexinduced muscle atrophy in L6 myotubes. As shown in Fig. 4a , at a Dex concentration of 2 μM, the inhibition of cell survival was approximately 19%. Additionally, Dex-mediated inhibition of cell survival was significantly alleviated by DM in a dose-dependent manner. Moreover, Dex induced a substantial decrease in the myofibrillar protein MHC expression, which was dose-dependently prevented by DM (Fig. 4b and 4c) . The greatest protective effect of DM was observed at the 10 μM dose; thus, we used this dose in subsequent experiments. Furthermore, Dex reduced the myotube diameter by approximately 26%, which was also prevented by DM (Fig. 4d) . Together, these results suggested that DM efficiently protected against Dex-induced cell death and muscle atrophy in vitro. 
DM improved mitochondrial morphology, rescued the reduced mtDNA content and repressed Dex-induced collapse of mitochondrial membrane potential (Δψm) in vitro
To assess the effects and underlying mechanisms of DM on mitochondrial function during muscle atrophy in vitro, we first evaluated the related protein expression. As shown in Fig. 5a -b and 5e-f, DM dose-dependently restored the Dex-mediated reductions in PGC-1α, TFAM, mfn2 and Tom20 protein levels and inhibited Dex-mediated increased expression of drp1, while it had no significant effect on mfn1 and OPA1 expression. Moreover, PGC-1α siRNA transfection markedly inhibited DM-induced PGC-1α activation accompanied by decreased expression of TFAM and mfn2, while the expression of drp1 was not affected (Fig. 5c and  5d ). Similar results were observed for TFAM, mfn2 and drp1 levels in the mitochondrial subfractions ( Fig. 5g and 5h) . These results suggested that DM activated the PGC-1α/TFAM and PGC-1α/mfn2 signaling pathways. To determine whether the PGC-1α/TFAM and PGC-1α/mfn2 signaling pathways mediated the effects of DM on the mitochondria, we applied PGC-1α siRNA, TFAM siRNA and mfn2 siRNA on L6 myotubes. The effects of downregulation of TFAM and mfn2 by specific siRNAs were evaluated in the mitochondrial subfractions. As shown in Fig. 5i -l, the TFAM and mfn2 levels after the siRNA treatments were significantly lower compared to those of the control siRNA-treated group, suggesting that the siRNAs successfully inhibited TFAM and mfn2 expression. To gain insight into the mitochondrial morphology, we incubated L6 myotubes with MitoTracker probes. As shown in Fig. 6a , the mitochondria displayed elongated and filamentous morphology in the control group. Following Dex treatment, the mitochondrial architecture was dramatically altered from that of the control group as demonstrated by punctate and highly fragmented mitochondria with a discontinuous network. DM treatment blocked Dex-induced excessive mitochondrial fragmentation and increased the filamentous mitochondria. In a further analysis, we found that Dex reduced mitochondrial mass, which was prevented by DM treatment (Fig. 6b) . However, PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection abolished these effects of DM ( Fig. 6a and 6b) . Similar results were observed for the mtDNA content (Fig. 6c) .
Next, we measured the effects of DM on Δψm in L6 myotubes using the JC-1 probe. As shown in Fig. 6d and 6e , Dex decreased the ratio of red to green fluorescence, indicating the depolarization of Δψm, while DM treatment significantly repressed Dex-induced dissipation of Δψm. However, PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection abolished the effect of DM on Dex-induced changes of Δψm. Together, these results suggested that DM improved mitochondrial morphology, rescued the reduced mtDNA content and repressed the collapse of Δψm through the PGC-1α/TFAM and PGC-1α/mfn2 signaling pathways in vitro.
DM ameliorated mitochondrial dysfunction and suppressed oxidative stress in vitro
We measured oxygen consumption rates (OCR) to confirm the hypothesis that mitochondrial function was increased by DM treatment in Dex-treated myotubes in vitro. The results showed that Dex reduced the mitochondrial respiration capacity, including basal respiration, ATP potential and maximal respiration, all of which were improved by DM treatment (Fig. 7a and 7b) . However, PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection impaired DM-induced mitochondrial respiratory recovery (Fig. 7a and 7b) . Then, the activities of mitochondrial respiratory chain complexes in L6 myotubes were measured. As shown in Fig. 7c and ATP synthase. DM treatment also tended to restore the activity of complex II, although there was no significant difference between any DM-group and Dex-group. However, PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection abolished the stimulatory effects of DM on the activities of complexes I and IV and ATP synthase. Similar alterations were observed in ATP levels using the corresponding assay kits (Fig. 7g) . Next, we measured intracellular ROS levels using the fluorescent probe DCFH-DA. As shown in Fig. 7h , Dex markedly increased cellular ROS levels, which was alleviated by DM treatment. However, PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection abolished the effect of DM on ROS levels. The superoxide anion (O 2
•− ) generated in mitochondria is the primary ROS; thus, we evaluated the mitochondrial-derived O 2
•− levels in myotubes labeled with MitoSOX Red to investigate the effect of DM on mtROS production. As shown in Fig.  7i and 7j, DM treatment notably blocked Dex-induced mitochondrial-derived O 2
•− elevation in myotubes. However, this effect of DM was sharply abolished by PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection. Similar results were observed for the protein carbonyl levels and MDA content ( Fig. 7k and 7l) . Together, these results suggested that DM reversed mitochondrial dysfunction through PGC-1α/TFAM and PGC-1α/mfn2 signaling pathways in vitro.
DM inhibited FoxO3a-mediated protein degradation and increased Akt/mTOR pathway dependent protein synthesis by improving mitochondrial function through the PGC-1α/ TFAM and PGC-1α/mfn2 signaling pathways
Previous studies have revealed that FoxO3a plays a pivotal role in the skeletal muscle atrophy program, as it modulates the expression of several factors in the ubiquitin-proteasome proteolytic pathway [42] . To determine whether DM regulates these critical components associated with muscle atrophy, we examined the protein levels of FoxO3a and the specific ubiquitin ligases, atrogin-1 and MuRF1. Treatment with DM at 100 and 200 mg/kg body weight markedly inhibited the Dex-mediated increased expression of FoxO3a, atrogin-1 and MuRF1 in vivo ( Fig. 8a and 8b) . Similar results were observed in L6 myotubes (Fig. 8c and  8d) . Moreover, the decrease in MHC content, as well as the increase in atrogin-1 and MuRF1 expression upon Dex treatment, were all normalized by FoxO3a siRNA transfection (Fig. 8e  and 8f ). To further characterize the mechanisms mediating the effects of DM on Dex-induced muscle atrophy models, we measured the Akt/mTOR signaling pathway, a crucial pathway regulating protein synthesis and muscle hypertrophy [43] . Both in vivo and in vitro results demonstrated that treatment with DM restored the Dex-mediated reductions in p-Akt and p-mTOR protein levels (Fig. 9a-d) . Moreover, DM also reactivated S6K (Fig. 9a-d) , an effector in protein synthesis and a downstream signaling molecule in the Akt/mTOR pathway [44] . Furthermore, pretreatment with Akti (Akt inhibitor) and rapamycin (mTOR inhibitor) markedly blocked the DM-induced increased expression of MHC and p-S6K (Fig. 9e and  9f ). These data indicated that DM inhibited protein degradation by inactivating FoxO3a and 
Discussion
Skeletal muscle plays a crucial role in human locomotion, energy metabolism, and the release of multiple types of myokines [45] . Excessive loss of muscle mass can compromise physical function, impair the efficacy of many different therapeutic treatments, and increase morbidity and mortality [3] . Thus, the development of countermeasures to block or attenuate muscle atrophy will improve quality of life and survival. Although several potentially interesting therapeutic targets for treating muscle atrophy have already been identified, an effective and safe drug that can counteract muscle atrophy is not yet clinically available [3] . Drugs such as ghrelin, clenbuterol and testosterone have been shown to prevent muscle atrophy under several wasting conditions, but their clinical applications are limited because of concerns regarding potential side effects, such as an increased risk of developing prostate hypertrophy, insulin resistance, and cardiac arrhythmias [46] . Therefore, further research is needed to develop effective and safe therapeutic avenues for muscle atrophy.
Natural products, mostly from plant sources, contain a range of bioactive components and have a long history in the traditional treatment of many diseases. Considering that many medicinal plants and natural products are considered by the public as a safe and cost-effective alternative to synthetic drugs [47] , natural product libraries may be a valuable source of preventive and therapeutic agents for muscle atrophy. Flavonoids, which exist ubiquitously in vegetables, fruits, teas, and medicinal plants, possess a wide range of health benefits [48] . In recent years, the effects of flavonoids on muscle atrophy under various conditions have received increased attention. Quercetin has been shown to prevent obesity and disuse- induced muscle atrophy [49] [50] . Baicalin and epigallocatechin-3-gallate were reported to attenuate skeletal muscle atrophy caused by cancer cachexia [51] [52] [53] . A recent study suggested that delphinidin could suppress Dex-induced MuRF1 expression in myotubes [54] .
In the present study, we focused on DM, a promising natural compound for food use, due to its abundance, broad range of health benefits and long history of safe consumption [17] . Our previous studies showed that supplementation of DM for 2 weeks had no significant effect on body weight and muscle weight in normal SD rats. To investigate the effects of DM on Dex-induced muscle atrophy, DM was administered for 2 weeks prior to Dex treatment as a preventive approach. The results suggested that DM treatment partially prevented muscle loss and myofiber CSA decrease in Dex-treated rats, which contributed to the restoration of muscle strength by DM. Moreover, the decreases in MHC content and myotube diameter, as well as the increase in ubiquitin E3 ligases (atrogin-1/MuRF1) expression in Dextreated myotubes, were all sufficiently normalized by DM treatment. These data identified new properties of DM, namely, the ability of DM to attenuate Dex-induced muscle atrophy. Furthermore, our study provided new insight into the potential mechanisms underlying the protective effects of DM on Dex-induced muscle atrophy, in which mitochondrial function regulation may play an important role. GCs play a crucial role in muscle atrophy observed in various pathological conditions [55] . Importantly, a recent study indicated that mitochondrial dysfunction has a central role in Dex-induced muscle atrophy models and that resveratrol can reverse muscle atrophy by improving mitochondrial function [12] . Mitochondrial function is affected by changes in morphology and abundance [7] . In this study, ultrastructural observation by TEM indicated that DM treatment attenuated Dex-induced mitochondrial swell and cristae disarray in GAS muscles, and the mitochondrial network visualized by MitoTracker probes showed that DM treatment conferred resistance to mitochondrial fragmentation in myotubes. Moreover, both in vivo and in vitro results demonstrated that DM treatment prevented the decrease in the mtDNA content. Concomitant with these changes, mitochondrial function, reflected by mitochondrial membrane potential, mitochondrial respiratory chain complex activities and ATP levels, were all improved by DM in Dex-induced muscle atrophy models. Our results demonstrated clear evidence that DM reversed Dex-induced mitochondrial dysfunction, which was crucial for preventing Dex-induced muscle atrophy. We further examined the mechanisms by which DM exerted its action on mitochondrial function. As PGC-1α is known to regulate mitochondrial function by modulating genes involved in mitochondrial biogenesis and dynamics [6] , we focused on the PGC-1α signaling pathway in the regulation of mitochondrial biogenesis and dynamics by DM in Dex-induced muscle atrophy models. Mitochondrial biogenesis is important for determining mitochondrial content and function, and compounds capable of stimulating mitochondrial biogenesis have shown potential as treatments for a wide range of diseases [56] . Quercetin and resveratrol can promote mitochondrial biogenesis and attenuate mitochondrial dysfunction in skeletal muscle during disuse-induced muscle atrophy [14, 57] . Our previous study suggested that DM improved mitochondrial biogenesis in skeletal muscle via upregulation of the PGC-1α signaling pathway during hypobaric hypoxia conditions [25] . In the present study, we found that DM enhanced mitochondrial biogenesis via activation of the PGC-1α/TFAM signaling pathway, which was closely associated with the restoration of mtDNA content and mitochondrial mass in Dex-induced muscle atrophy models. Furthermore, mitochondria are dynamic organelles that constantly remodel their architecture through the fusion and fission processes. Mfn2, a mitochondrial fusion protein crucial for the maintenance of the mitochondrial network architecture, is induced during myogenesis and abundantly expressed in skeletal muscle [58] . Previous studies have suggested that mfn2 deficiency in muscles leads to mtDNA depletion, impaired OXPHOS, decreased mitochondrial membrane potential, and oxidative stress [59] [60] [61] . Moreover, muscle mfn2 protein levels were repressed in several catabolic conditions [62] [63] [64] [65] . Lokireddy et al. showed that Dex increased mfn2 degradation in myotubes [66] , and Liu et al. found that Dex decreased mfn2 levels in the TA muscles of mice [12] , while Troncoso et al. reported that Dex had no influence on mfn2 expression in myotubes [67] . Our results suggested that Dex significantly decreased mfn2 expression levels in skeletal muscle both in vivo and in vitro. DM promoted mitochondrial fusion as shown by the restoration of mfn2 expression. Furthermore, PGC-1α has been shown to induce the expression of mfn2 in muscle cells [68] ; thus, DM might upregulate mfn2 expression through the activation of PGC-1α. As expected, in vitro PGC-1α siRNA transfection markedly inhibited DM-induced mfn2 expression, suggesting that DM activated the PGC-1α/ mfn2 signaling pathway. We also evaluated the expression of the key mitochondrial fission protein drp1. The results showed that Dex increased drp1 levels in vitro, while it had no significant effect on drp1 levels in vivo. DM blocked Dex-mediated increased drp1 expression in vitro, but it had no effect on drp1 expression in vivo. Although there are differences regarding the effects of Dex or DM on drp1 expression in the whole muscle lysates between in vivo and in vitro studies, the levels of drp1 in the mitochondrial subfractions were increased by Dex but were decreased by DM both in vivo and in vitro, suggesting that DM attenuated Dex-mediated elevated mitochondrial fission via the inhibition of drp1 recruitment to the mitochondria. Additionally, we found that in vitro PGC-1α siRNA transfection had no effect on drp1 expression both in the whole muscle lysates and the mitochondrial subfractions. The present study further demonstrated that PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection abolished the protective effects of DM on mitochondrial architecture, mtDNA content and mitochondrial function, suggesting enhanced mitochondrial biogenesis through the PGC-1α/TFAM signaling pathway and improved mitochondrial dynamics through the PGC-1α/mfn2 signaling pathway as likely explanations for the restoration of mitochondrial function in Dex-induced muscle atrophy models treated with DM. In addition, there may be an interplay between mitochondrial biogenesis and mitochondrial dynamics [69] . In our study, we found that TFAM siRNA transfection resulted in discrete fragmented mitochondria, and mfn2 siRNA transfection reduced the mtDNA content and mitochondrial mass. Based on these findings, we speculated that DM exerted its action on mitochondrial function through the orchestration of mitochondrial biogenesis and mitochondrial dynamics via the activation of the PGC-1α signaling pathway.
Oxidative stress is inseparably linked to mitochondrial dysfunction as mitochondria are both primary sources and targets of ROS [70] . The excessive mtROS production causes oxidative stress that increases oxidative damage to DNA, proteins and lipids not only in mitochondria but also in other cellular compartments, which can in turn exacerbate mitochondrial dysfunction and cause further damage to cells and tissues [71] [72] [73] . Several reports have indicated that Dex induces oxidative stress in osteoblast cells, hippocampal cells and thymocytes [74] [75] [76] , but few studies have examined the effects of Dex on oxidative stress in skeletal muscle. We found that Dex markedly increased cellular ROS levels and caused oxidative damage to proteins and lipids in skeletal muscle, which were notably blocked by DM treatment. The observed protective effects of DM on Dex-induced oxidative stress might be attributed to the decreases in mtROS generation. In addition, given that DM has powerful antioxidant and free radical scavenging capabilities [17] and PGC-1α is also a key factor that regulates the gene expression of antioxidant enzymes [77] , it is possible that DM inhibits oxidative stress by directly scavenging excessive ROS or by increasing antioxidant enzyme activities, which could contribute to the improvement of mitochondrial function. Further experiments should be performed to clarify the mechanisms responsible for the protective effects of DM on mitochondrial dysfunction and oxidative stress in Dex-induced muscle atrophy models.
Previous studies suggested that mitochondrial dysfunction is involved in the activation of proteolytic systems [7] , and the muscle proteins modified by oxidative stress are prone to proteolysis [78] . In addition, the activated proteolytic systems can in turn induce the breakdown of mitochondrial proteins and exacerbate mitochondrial dysfunction, which further accelerate the proteolysis of skeletal muscle proteins [12] . In this study, we focused on the ubiquitin-proteasome system, the main regulatory mechanism of protein degradation in skeletal muscle. The results indicated that DM blocked FoxO3a-mediated activation of ubiquitin-proteasome dependent proteolytic pathway by improving mitochondrial function. Moreover, previous reports demonstrated that muscle wasting stimuli resulted in enhanced FoxO3a-mediated activation of Mul1, which in turn ubiquitinates and degrades mfn2, leading to mitochondrial dysfunction and muscle atrophy [66] . Thus, DM might improve mitochondrial function through the inhibition of FoxO3a. In addition, PGC-1α was shown to repress FoxO3a-dependent transcription of atrophy-specific genes [79] . Therefore, DM may attenuate Dex-induced muscle atrophy independent of its action on mitochondrial function.
Muscle mass is determined by both the rates of protein synthesis and degradation [80] . Thus, we also investigated the effects of DM on the Akt/mTOR signaling pathway, which plays a pivotal role in activating protein synthesis. The repression of the Akt/mTOR pathway by Dex was alleviated by DM, suggesting that DM was also effective in attenuating the reduced protein synthesis. Akt signaling has been shown to repress the expression of transcription factors in the FoxO family and then block the protein degradation pathways [80] . Moreover, mTOR signaling could be also directly inhibited by FoxO proteins [81] . Therefore, the protein synthesis and degradation processes are intimately connected, and DM improved protein metabolism through FoxO3a-and Akt/mTOR-dependent mechanisms. Moreover, PGC-1α siRNA, TFAM siRNA and mfn2 siRNA transfection inhibited the DM-induced activation of the Akt/mTOR signaling pathway. Thus, the ability of DM to counteract the decreased protein synthesis was closely linked to its ability to improve mitochondrial function. Furthermore, emerging studies have indicated that mTOR stimulates mitochondrial biogenesis and regulates mitochondrial function [82] . Therefore, DM may prevent Dex-induced muscle atrophy by coordinating protein synthesis and mitochondrial function. Further experiments should be performed to explore additional mechanisms responsible for the protective effects of DM on Dex-induced muscle atrophy.
Although the present study suggested that DM effectively attenuated Dex-induced muscle atrophy in laboratory studies, given that muscle atrophy is a complex process that occurs as a consequence of multiple and interrelated stressors [83] , it is necessary to investigate the effects of DM on other types of muscle atrophy as well as the underlying mechanisms. Moreover, in view of the good efficacy and safe properties of DM, DM-containing capsules are sold in the US as a nutraceutical supplement to prevent alcohol hangovers [84] , and our previous randomized controlled clinical trial suggested that DM could improve liver steatosis in patients without any adverse events [85] . These studies demonstrated that DM may be developed as innovative and effective therapeutic agents. Future clinical randomized studies are needed to investigate whether DM has anti-muscle atrophy effects.
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